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Abstract. Background: Blood stream infections (BSIs) represent a major complication of allo-
SCT and are a major cause of morbidity and mortality during and after bone marrow aplasia. 
Objectives: The objective of this study was to describe the incidence and outcome of BSIs in a 
cohort of patients submitted to allo-SCT, in order to track changes of the epidemiology and 
bacteria resistance.  
Methods: We retrospectively analyzed the microbiological data of 162 patients allotransplanted 
in Brescia University Hospital, over a period of 6 years. 
Results: Eighty patients experienced a BSIs for a total of 119 isolates. In 77 cases (65%) a Gram 
positive bacteria was isolated, being coagulase negative Staphilococci the most frequent species 
(77% of the cases). In 42 cases (35%) a Gram negative bacteria was isolated (E. coli 57% and P. 
aeruginosa 24%). Fluoroquinolones resistance was frequent (90% for S. epidermidis, 92% for E. 
coli, 90% for P. aeruginosa). Methycillin resistance of S. epidermidis was 100%, 76% of E. coli 
were ESBL positive and among P. aeruginosa resistance to carbapenems was 40%. The 2 years 
overall survival of patients with BSIs vs patients without BSIs was 46% vs 60% (HR1,48, 
p=0,07). P. areuginosa and E. coli were the species with the highest mortality (50% and 33%, 
respectively).  
Conclusions: These data confirm that BSIs, mainly sustained by Gram positive bacteria, are 
frequent in allotransplanted patients (50% of the cases) and may influence the outcome of 
allotransplanted patients, being antibiotics resistance highly frequent among these bacteria.  
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Introduction. Allogeneic stem cell transplantation 
(allo-SCT) is widely considered a curative option 
for many hematological malignancies, particularly 
for acute leukemias. Morbidity and mortality of 
allo-SCT are mainly influenced by relapse and 
transplant-related factors (e.g. conditioning 
toxicity), infections and immunological events, 
such as graft versus host disease (GVHD).
1-13
 
Blood stream infections (BSIs) represent the most 
frequent infective event in allotransplanted 
patients, and their incidence may vary from 20 to 
70%.
1-12
 Prolonged neutropenia, gastro-intestinal 
mucosal damage and extensive use of central 
venous catheters (CVC) are the major risk factors 
for BSIs.
3,5,7,9
 
Usually BSIs occur during the pre-engraftment 
phase, but they can occur in later phases too.
5,10
 
Prophylactic antimicrobical therapy is 
conventionally used during agranulocytosis, as 
well as an empirical use of antibiotics in case of 
suspected BSI, despite it is well known that 
multidrug resistant bacteria may emerge.
14-17
 At 
present, a selective gut decontamination, with the 
aim to reduce the translocation of intestine Gram 
negative bacteria from the gut to periheral blood, 
is conventionally based on fuoroquinolones, but 
this policy, during the last decade, induced the 
emergence of Gram negative fluoroquinolones 
resistant bacteria and an increase in Gram positive 
infections.
12,15
 
In the event of a suspected bacterial infection, 
the common clinical practice in patients submitted 
to allo-SCT is to identify the specie involved in 
the infection as soon as possible, and to use a 
targeted antibiotic therapy, based on the 
antibiograms. However, it should be considered 
that only 30-40% of the febrile episodes in patients 
submitted to allo-SCT can be defined as BSIs. In 
fact, more than 50% of blood cultures (BCs) 
during fever do not give rise to any bacteria, and, 
as a consequence, the antimicrobical therapy is 
often empirical and, thus, the surveillance of 
infections in a bone marrow transplant Unit is 
mandatory, in order to correctly drive the use of 
empirical therapy.  
The aim of this retrospective study was to 
describe the incidence and outcome of BSIs in a 
cohort of 162 patients submitted to allo-SCT, over 
a period of 6 years of transplant activity and to 
compare these data with the ones reported in the 
litterature, in order to track changes of the 
epidemiology and bacteria resistance.  
Patients and Methods. This retrospective analysis 
was pointed out on the BSIs occured from January 
2010 to December 2015 in the Bone Marrow 
Transplant Unit of Brescia University Hospital in 
Italy. Data were analysed from the computerized 
database including all the informations of patients 
submitted to allo-SCT. At the same time, clinical 
charts of the patients who experienced a BSIs were 
reviewed. All the BSIs occuring during the patient 
hospitalization were recorded.  
 
Definitions: BCs were obtained from peripheral 
blood (PB) and CVC at fever onset (defined as 
body temperature of at least 38°C) or whenever in 
suspicion of infection. BSIs were defined as 
isolation of bacterial or fungal pathogen from at 
least 1 blood culture, with the exception of 
bacteria commonly considered skin contaminants 
(e.g. coagulase negative Staphylococci or 
Corynebacteria), for whom at least two positivity 
were requested. The CVC related infection was 
defined when a positive CVC-BC preceeded by 
two hours the positivity of a PB-BC. CVC 
contamination was defined by the presence of a 
positive CVC-BC and a negative PB-BC. For the 
porpuse of this study, CVC contaminations were 
included in the analysis and considered as 
bacteremia, considering that the clinical 
management of these cases is not different with 
respect to the clinical management of any other 
BSI. Subsequent positivity of a blood culture after 
at least 7 days following first positivity was 
considered as a separate BSI, if blood culture 
negativity was defined, in the meanwhile. Gram 
negative bacteria were considered extended 
spectrum beta-lactamase (ESBL) producers 
according to the published laboratory tests.
18,19
 
Resistance to at least 3 antibiotics among 
ceftazidime or cefepime, piperacillin/tazobactam, 
ciprofloxacin, gentamicin, imipenem or 
meropenem were the basis for multi-drug 
resistance definition (MDR). For the definition of 
resistance we referred to the European Committee 
on Antimicrobial Susceptibility Testing 
(EUCAST) 2016.
20
 Briefly, the Minimal 
Inhibitory Concentrations (MIC) considered for 
antibiotics resistance were the followings: 
ceftazidime or cefepime > 8 mg/L for P. 
aeruginosa and > 4 mg/L for enterobacteria, 
respectively; piperacillin/tazobactam > 16 mg/L, 
cirpofloxacin > 1 mg/L, gentamicin > 4 mg/L and 
 
www.mjhid.org Mediterr J Hematol Infect Dis 2017; 9; e2017036                                                                Pag. 3 / 10 
 
carbapenems > 8 mg/L both for P. aeruginosa and 
for enetrobacteria.  
  
Transplantation procedures: The patients included 
in this analysis were transplanted during the 6-
years period with either reduced intensity 
conditioning regimen (RIC) or myeloablative 
conditioning regimen (MAC), depending on age, 
disease type and comorbidity. All the RIC 
regimens were fludarabine and thiotepa or 
busulfan-based, whereas the MAC regimens were 
busulfan or total-body irradiation-based. GVHD 
prophylaxis consisted on cyclosporine and 
methotrexate, with the addition of anti-thymocyte 
globulin (ATG) in cases of matched unrelated 
donors (MUD). In the haploidentical setting, 
GVHD prophylaxis consisted on cyclosporine, 
mycophenolate and post-transplant 
cyclofosfamide.
21
 HLA matching was based on 
molecular four digits typing of a minimum of 4 
loci (A, B, C, DRB1). Peripheral blood was used 
as the preferred stem cells source. Acute and 
chronic GVHD were graded as previously 
published.
22,23
 All the patients had a Groshong 
CVC at the time of conditioning regimen intiation. 
At hospital admittance, mucosal swabs (nasal, 
mouth, axillary, rectal and genital) were performed 
in all the patients, with the objective to detect 
bacterial colonization. In case of positive coltures, 
antibiograms were included in the laboratory 
report, with focus on vancomycin resistant 
Enterococci (VRE), bacteria ESBL-producing or 
carbapenemase-producing enterobacteriacae. 
Engraftment was defined as an absolute count of 
neutrophils greater than 500/mmc for at least three 
consecutive days. 
 
Porphylaxis and management of infections: All the 
patients received standard antimicrobical 
prophylaxis with levofloxacine, acyclovir and 
fluconazole from day 0. Levofloxacine was 
discontinued at the engraftment. Patients with a 
previous history of possible or probable invasive 
fungal infection (IFI) received secondary anti-
fungal prophylaxis with liposomal B-
amphotericine. Pneumocystis carinii prophylaxis 
with trimethoprim sulphametoxazole was started 
at the time of neutrophil engraftment. Pre-emptive 
therapy for CMV with gancyclovir was started in 
the event of CMV-DNA positivity as detected by 
quantitative real-time PCR, in at least two 
examinations within 1 week.  
As previosuly described, the diagnostic work 
up at fever onset, or in case of any symptom of 
infection, consisted on blood cultures collection, 
collection of culture samples from any site with 
suspect infection and chest X-ray. Then, 
floroquinolone prophylaxis was stopped and broad 
spectrum i.v. antibiotics were started. Empirical 
antimicrobical therapy consisted on ceftazidime or 
piperacillin + tazobactam with or without the 
addition of glycopeptide (e.g. teicoplanine) 
depending on the clinical conditions of the patient 
(e.g. hypotension, gastrointestinal mucositis). In 
case of fever persistance after 72 hours of broad 
spectrum antibiotics with persistent negativity of 
blood cultures, the diagnostic work-up for an IFI 
was started. This consisted on a high-resolution 
CT scan of the lung, blood samples for 
galactomannan dosage and broncoscopy with 
bronco-alveolar lavage and tissue specimen 
whenever clinically possible. In case of possible 
IFI according to the published criteria,
24
 empirical 
therapy was started, using liposomal B-
amphotericine or caspofungin.  
 
Statistical analysis: For the purpose of descriptive 
analysis, continuous variables were summarized as 
median and range, categorical as frequencies and 
percentages. Differences between groups were 
analyzed with Chi-square and Mann-Whitney U 
tests for categorical and continuous variables, 
respectively. Survival analysis was performed 
according to Kaplan-Meier method and log-rank 
test was used to evaluate differences between 
subgroups. All tests were 2-sided and p values 
below 0.05 were considered statistically 
significant. Analyses were carried out with EZR 
software version 1.33.
25
 
 
Results. 
Patients' characteristics: From 2010 to 2015, 162 
patients with hematological malignancies were 
submitted to allo-SCT. Among these, 80 patients 
(49%) experienced a BSI, for a total of 119 
isolates. Eighty-two (51%) out of 162 patients had 
no BSIs. Patient demografics are reported in Table 
1. Briefly, the median age was 48 years (17-68), 
approximately two thirds of the patients were 
transplanted for acute leukemias (AL) (93/162, 
57%) and 70/162 (43%) patients were transplanted 
in 1st complete remission (CR). Seventy-one 
(44%) out of 162 patients received a MAC, 122 
(76%) were transplanted using peripheral blood
 
www.mjhid.org Mediterr J Hematol Infect Dis 2017; 9; e2017036                                                                Pag. 4 / 10 
 
Table 1. Clinical and biological characteristics of the 80 allotransplanted patients with BSI vs the 82 allotransplanted patients without BSI. 
Variables Patients submitted to allo-SCT (n=162) 
 N % 
Sex 
- M 
- F 
 
103 
59 
 
64 
36 
Age (Median – range) 48 (17-68) - 
Disease 
- AL/MDS 
- HL 
- NHL 
- MM 
- Other 
 
93 
4 
14 
19 
22 
 
57 
9 
9 
12 
13 
Disease phase 
- 1st CR 
 
70 
 
43 
Patients with pre-SCT colonization 
- ESBL producer enterobacteria 
- Carbapenem-resistant enterobacteria 
- MDR P. aeruginosa 
- VRE 
 
6 
7 
0 
0 
 
4 
4 
0 
0 
Conditioning 
- MAC 
- RIC 
 
71 
91 
 
44 
56 
SC source 
- BM 
- PB 
- CB 
 
33 
122 
7 
 
20 
76 
4 
Donor 
- Sibling 
- MUD 
- Haplo 
- CB 
 
58 
86 
11 
7 
 
36 
53 
7 
1 
GVHD prophylaxis 
- CyA + MTX + ATG 
- CyA + MTX 
- CyA + MMF + ATG 
- CyA + MMF + other 
 
86 
58 
7 
11 
 
53 
36 
4 
7 
aGVHD  2 56 35 
cGVHD (extensive) 19 12 
Follow up (months; median – range) 14 (0 - 68) - 
List of abbreviations: AL: acute leukemia; MDS: myelodisplastic syndrome; HL: Hodgkin Lymphoma; NHL: Non Hodgkin Lymphoma; 
MM: Multiple Myeloma; CR: Complete Remission; VRE: vancomycin-resistantant enterobacteria; MAC: Myeloablative Conditioning; RIC: 
Reduced Intensity Conditioning; BM: Bone Marrow; PB: Peripheral Blood; CB: Cord Blood; MUD: Matched Unrelated Donor; Haplo: 
Haploidentical Transplant; CyA: Cyclosporine A; MTX: Methotrexate; ATG: Anti-Thymocyte Globulin; MMF: Mophetil Mycophenolate; 
GVHD: Graft Versus Host Disease; NS: non significant. 
 
stem cells (PBSC) and 86 (53%) received a 
transplant from a MUD. During patients' follow up 
the incidence of aGVHD grade  2 was 35% 
(56/162 cases) and the incidence of extensive 
cGVHD was 12% (19/162 cases). The incidence 
of possible/probable IFI was 35% (57/162 cases) 
and the incidence of CMV reactivation was 59% 
(95/162 cases). The median follow 14 months 
(range 0-68). No significant differences were 
observed comparing the clinical and biological 
characteristics of patients with BSIs (BSI-pos) and 
patients without BSIs (BSI-neg) (data not shown). 
As a consequence we were not able to identify any 
factor possibly correlated with the risk of 
developing a BSI.  
 
Bloodstream infections: One-hundred nineteen 
isolates were obtained from the blood samples of 
80 patients with BSI (BSI-pos). The median time 
of positivity of BCs was 19 days from transplant 
(range day -4 to day +921). In 42/80 patients 
(52%) the positive blood culture was detected 
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before day +19 from allo-SCT. Half (n° 59) of the 
positive BCs derived from PB samples and half 
(n° 60) could be considered CVC-related. Thirty-
five out of 119 (29%) positive BCs were 
considered as contamination as previously defined. 
Therefore, 84/119 (71%) of the BSIs could be 
considered real bacteremia according to 
microbiological criteria. In 27/84 cases (24%) the 
BSI could be defined CVC-related, according to 
the above reported criteria. 
Considering epidemiology, 77/119 (65%) and 
42/119 (35%) BCs were positive for Gram 
positive and Gram negative bacteria, respectively. 
Data on the different species distribution is 
reported in Table 2. Polimicrobical BSIs were 
found in 11/119 (9%). In one patient the BCs were 
positive for a Gram positive bacteria (S. 
heamolyticus) toghether with a Candida 
parapsilosis. 
Antibiotics resistance is reported in Table 2. S. 
epidermidis was resistant to methycillin in all the 
cases and to fluoroquinolones in 90% of the cases. 
Sixty-seven percent of E. coli were ESBL 
producers and 92% were resistant to 
fluoroquinolones. Moreover, 40% and 90% of P. 
aeruginosa were resitant to carbapenems and 
fluoroquinolones, respectively. No 
carbapenemase-producing K. pneumoniae (KPC) 
was isolated in our series. 
When we analyzed the clinical and transplant 
characteristics of the patients who experienced a 
Gram positive or a Gram negative BSI, we found 
that: patients with Gram negative BSIs were more 
frequently affected by acute 
leukemia/myelodisplastic syndrome (83% vs 54%, 
p=0,006) and were more frequently transplanted 
from cord blood (14% vs 3%, p=0,04). On the 
other hand, patients with Gram positive BSIs were 
more frequently allotransplanted using a RIC 
regimen (69% vs 51%, p=0,004).  
Gram positive / Gram negative ratio was 1 and 
3,2 considering early BSIs (before day +19) vs late 
BSIs (after day +19) (p= 0,004). This difference 
was related to the reduction of Gram negative 
bacteremia after recovery from agranulocytosis 
(p=0,001). When we separately analyzed the 
clinical and biological characteristics and the 
different species distribution according to the time 
of positivity of the blood culture (before or after 
day +19 from allo-SCT), we were not able to 
identify any significant difference (data not 
shown). With the aim to identify factors correlated 
with the time of development of BSIs (during or 
after aplasia), we analyzed the clinical and 
biological variables of patients with positive BCs, 
according to the time of BC positivity [before 
engraftement (n=47) and after engraftment 
(n=33)]. We found that BSIs in patients 
transplanted from a sibling donor were more 
frequent after engraftement (45% vs 23%; p=0,05) 
and that patients who developed a BSI during 
aplasia had a higher incidence of IFI (47% vs 
24%; p=0,04).  
Forty-four (55%) out of 80 patients had an 
organ involvement together with the BSI. This was 
the lung in 57% of the cases (25/44 cases), and the 
gut in 14% (6/44 cases). Within the 6 years of the 
observation time, we found a homogeneous Gram 
positive / Gram negative ratio in all the years, with 
the exception of 2012 and 2013, where we 
observed a reduction in the number of positive 
BCs (11 in 2012 and 13 in 2013) and a reduction 
in Gram positive / Gram negative ratio (1,2 in 
2012 and 0,6 in 2013). No statistical significant 
differences were observed comparing the number 
of positive BCs and the Gram positive / Gram 
negative ratio in the single years (data not shown).  
 
Pre-transplant microbiological-history: Twenty-
nine out of 80 (36%) patients with BSIs 
experienced other microbiological isolates during 
the treatment of the hematological disease before 
allo-SCT, for a total of 55 isolates. In 12/29 cases 
(34%) the specie responsible of the BSI before and 
after the transplant treatment phase was the same, 
and the antibiograms were comparable. In 27 
(49%) and 28 (51%) out of 55 BSIs a Gram 
positive and Gram negative bacteria was isolated, 
respectively. Among Gram positive and Gram 
negative bacteria, coagulase negative 
Staphylococci (14/27, 52%) and E. coli (22/28, 
76%) were mostly represented.  
Thirteen out of 162 (8%) patients of this series 
were colonized by resistant microorganisms 
(ESBL producers, carbapenem-resistant 
enterobacteria, MDR P. aeruginosa and VRE). In 
particular, 5/80 (6%) of patients who developed a 
BSI were colonized by carbapenem-resitant E. 
coli. All these patients experienced a BSI caused 
by carbapenem-resistant E. coli. Moreover, 8/82 
(10%) patients who did not experienced a BSI 
were colonized by resistant microorganisms (E. 
coli ESBL producers in 5 cases, E. coli 
carbapenem-resistant in 2 cases and K. pneumonia 
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Table 2. Antibiotic resistance of the 119 species isolated from 80 allotransplanted patients. 
 N° of BCs (%) MRSA (%) Penicillin-R (%) Quinolones-R (%) 
GRAM positive 77/119 (65) // // // 
S. epidermidis 42/77 (55) 100 100 90 
S. haemolyticus 9/77 (12) 100 100 100 
S. hominis 8/77 (10) 75 75 100 
S. aureus 1/77 (1) 100 0 100 
S. warneri 1/77 (1) 0 0 0 
E. faecalis 6/77 (8) // 33 100 
E. faecium 3/77 (4) // 33 100 
C. jeikeium 3/77 (4) // 100 100 
C. striatum 1/77 (1) // 0 0 
C. urealyticum 1/77 (1) // 0 0 
B. firmus 1/77 (1) // 0 0 
Difteroides 1/77 (1) // 0 0 
 N° of BCs (%) ESBL+ (%) Carbapenems-R (%) Quinolones-R (%) 
 
GRAM negative 42/119 (35)    
E. coli 24/42 (57) 67 0 92 
P. aeruginosa 10/42 (24) // 40 90 
A. baumanii 1/42 (2) // 0 100 
E. cloacae  1/42 (2) // 0 0 
R. radiobacter 1/42 (2) // 0 0 
K. pneumoniae 1/42 (2) 0 0 0 
S. liquefaciens 1/42 (2) // 0 0 
P. mirabilis 1/42 (2) // 0 0 
Salmonella ssp 1/42 (2) // 0 0 
S. maltophila 1/42 (2) // 0 0 
 
ESBL-producer in 1 case). No MDR P. 
aeruginosa or VRE were isolated.   
 
Outcome: The overall survival of the 80 BSI-
pos patients compared to the 82 BSI-neg patients 
is reported in Figure 1A. Fourty-seven out of 80 
BSI-pos patients (59%) vs 35/82 BSI-neg patients 
(43%) died during follow up (p=0,2). Considering 
the outcome according to the distribution of BSIs 
before (n=47) or after (n=33) the engraftement, no
statistical significant differences were observed 
(data not showed). Thirty out of 47 (64%) and 
17/33 (52%) patients with BSIs before and after 
engraftement died, respectively (p=0,27). The 
projected 2 years OS for patients with BSI vs 
patients without BSI is 46% vs 60% (HR 1.48, 
95% CI: 0,96-2,29; p=0,07). Major causes of death 
in the BSI-pos vs BSI-neg groups were: disease 
relapse (42% vs 55%; p= 0,37), infections (42% vs 
17%; p= 0,02), aGVHD (2% vs 8%; p= 0,36), 
cGVHD (5% vs 6%; p= 1,00) and toxixity (2% vs 
6%; p= 0,30). As reported in Figure 1B the 
transplant related mortality (TRM) among BSI-pos 
and BSI-neg patients was comparable (p=0,22). 
Fifteen out of 80 patients with positive BSI 
(19%), died because of the bacterial infection. 
Considering the 162 allotransplanted patients, the 
BSI related mortality was 9% (15/162 cases). Nine 
out of these 15 deaths (60%) were related to Gram 
positive bacteria, leading to a Gram positive 
related mortality of 12% (9/77 Gram + isolates). 
Six out of 15 infection-related deaths (40%) were 
caused by a Gram negative agent, leading to a 
Gram negative related mortality of 14% (6/42 
Gram negative isolates). Interestingly, we 
observed that among the Gram positive bacteria 
the mortality rate was 33% for Enterococci (3/9 
isolates), 22% for S. haemolyticus (2/9 isolates) 
and 10% for S. epidermidis (4/42 isolates).  
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Figure 1A. Overall survival of the 162 allotransplanted patients according to presence or not of a BSI. 
Figure 1B. Transplant related mortality of the 162 allotransplanted patients according to presence or not of a BSI. CI= Cumulative 
Incidence; TRM = Transplant Related Mortality 
Considering Gram negative bacteria, the 
mortality rate was 50% for P. aeruginosa (5/10 
isolates, in 1 case MDR, in 4 cases multisensible) 
and 4% for E. coli (1/24 isolates, ESBL producer).  
 
Discussion. Infective complications are commonly 
considered the most relevant event associated with 
increased morbidity and mortality in 
allotransplanted patients (1 - 12), and the 
microbiological surveillance of bacterial isolates 
in Transplant Units is a mainstay of good clinical 
practice. In this view, we collected the data on 162 
allotransplanted patients, 80 of whom (49%) 
experienced a BSI, over a period of 6 years of 
transplant activity. The total number of positive 
BCs in the period of observation was 119, 84 of 
whom (71%) could be considered as real 
bacteremia. 
Overall, our data are in line with previous 
reports, that cover a longer period (10-15 years), 
showing a predominance of Gram positive over 
Gram negative bacteria (65% vs 35%), being S. 
epidermidis (55%) and E. coli (57%) the 
predominant species among Gram positive and 
Gram negative BSIs
 
(Table 2).
4,5,6,8,12,16,17
 We 
were not able to identify clinical and transplant 
variables significantly associated with the 
development of BSIs, and this is probably related 
to the relatively low number of patients in each 
subgroup. Interestingly, patients with a Gram 
negative BSI were more frequently affected by 
acute leukemia or myelodisplastic syndrome 
(p=0,006) and were more frequently transplanted 
from cord blood (p=0,04). Although the number of 
patients in each group is relatively small to draw 
final conclusions, we can speculate that these 
differences may be caused by the intensive pre-
tranplant treatement, by the high prevalence of 
refractory disease among acute leukemia patients 
and by the delayed neutrophil recovery observed 
when a cord blood is used as stem cell source, 
respectively. On the other hand, a BSI sustained 
by a Gram positive bacteria was more frequent in 
patients allotransplanted using a RIC regimen 
(p=0,04). This may partially reflect the 
characteristics of these patients (e.g. frail and 
elderly patients). 
One point of interest in the field of bacterial 
infections is antimicrobical resistance.
14-17
 Our 
data confirm that this problem has now reached 
the highest level of criticism, as we observed 
fluoroquinolones resistance both among Gram 
positive (roughly 100%) and Gram negative 
(between 90 and 100%) bacteria, toghether with 
methicillin resistance among Gram positive 
bacteria (100% of the S. aureus, epidermidis and 
haemolyticus and 75% of the S. hominis) (Table 
2). This is in line with previously reported 
series
12,17
 and it is strongly associated with the 
large use of fluoroquinolones for prophylaxis 
during the aplastic phase, although this practice is 
commonly suggested by the most recently 
published guidelines.
26
 Considering these data, the 
debate on the utility of fluoroquinolones 
prophylaxis is still opened. This policy, indeed, 
may reduce the mortality of Gram negative 
bacteria, but other propylaxis are under 
investigation. Recently, Pohlen and Colleagues, 
reported on a study comparing ciprofloxacin 
versus colistin prophylaxis in AML patients during 
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neutropenia.
28
 Although this was not a randomized 
trial, ciprofloxacin prophylaxis was confirmed 
highly effective in reducing the incidence of 
infections (69% vs 79% for colistin; p=0,07), but 
was confirmed to be associated with 
fluoroquinolone resistance, as expected. 
Moreover, 67% of E. coli was ESBL producer and 
40% of P. aeruginosa was resistant to 
carbapenems, and this is similar to what 
previously reported.
12,15
 Interestingly, no KPC was 
isolated. This point is of interest, because currently 
data from the litterature suggest that 
carbapenemase-producing enterobacteriacae 
(namely KPC) is an emerging problem in 
hematological patients, particularly challenging 
among allotransplanted patients. As reported by 
Girmenia and Colleagues in a retrospective italian 
survey, the incidence of KPC infections in 
allotransplanted patients was 2%, with a high-risk 
of infections in colonized patients. Moreover, the 
infection related mortality was 64%.
27
 One 
possible explanation for the absence of KPC in our 
series may be related to the fact that we did not 
observe any pre-transplant colonization sustained 
by this bacteria. Alltogether these data enhance the 
importance of microbiobiological surveillance 
with the aim to promptly start patients' isolation 
and reduce MDR bacteria spreading. 
Looking at the species distribution per year in 
our series, the Gram positive / Gram negative 
ratio, as well as the isolated species, remained 
costant, with the exception of 2 years (2012 and 
2013), in which an overall reduction in BSIs and a 
reduction of the Gram positive / Gram negative 
ratio was observed . Although these differences do 
not reach the level of significance, they may be 
partially explained considering the different 
management of CVC in the years 2012 and 2013, 
when we had a single nurse dedicated to CVC 
medications. Considering the high incidence of 
CVC-related infections (24%), the adoption of 
clinical-care strategies such as CVC medication 
under optimal asepsis and by dedicated nurses 
may be the best way to prevent BSIs. 
Colonization by multiresistant microorganisms 
was detected in a small proportion of patients 
(13/162, 8%), and was mainly sustained by ESBL-
producer or carbapenem-resistant enterobacteria 
(namely E. coli). Due to the relatively small 
number of cases we could not compare the 
outcome according to colonization. We indeed 
observed that all the patients colonized by 
carbapenem-resistant E. coli experienced a BSI 
caused by a similar resistant microorganism.  
Moving from epidemiology to outcome, we 
observed that 15/162 allotransplanted patients 
(9%) died because of BSIs and this mortality rate 
is comparable to the one observed in other 
reports.
7,8,29
 P. aeruginosa can be still considered 
the major killer, irrespective of its resistance 
profile (5 deaths out of 10 cases – 50%, similarly 
to what reported by Collin et al - in one case only 
MDR). Enterococci, coagulase negative 
Staphylococci, and E. coli showed a mortality of 
33% (3/9 cases), 12% (6/51 cases) and 4% (1/24 
cases), respectively. It should be stressed that in 
12/15 (80%) of these bacteremia-related deaths 
other factors, such as GVHD or active disease at 
transplant, were present at the time of BSI. 
Moreover, we observed that the long term 
outcome of patients who experience a BSI was 
impaired with respect to those who do not 
experience this complication (2 years OS for 
patients with BSI vs patients without BSI: 46% vs 
60%; p=0,07). Although the TRM of the two 
groups is comparable (Figure 1B), the difference 
in mortality among patients with BSI and those 
without BSI is more evident after at least 12 
months from transplant. This may be partially 
related to the fact that bacteremia are present in 
the late phase of the transplant too and usually 
affects extremely frail patients, such as those with 
GVHD and chronic steroid treatment. In such 
critically hill patients, a bacteremia may rapidly 
and negatively influence the outcome.  
In conclusion, BSIs continue to be a significant 
event in allotransplanted patients, with Gram 
positive bacteria being the species at highest 
incidence and P. aeruginosa being the specie with 
the highest mortality. Routinely use of 
fluoroquinolone prophylaxis and prompt empirical 
antimicrobical therapy significantly reduces the 
mortality related to bacterial infections, but 
emergence of quinolones resistance in the great 
majority of Gram positive and negative species 
remain an unsolved issue. Even though further 
studies on prophylaxis in allotransplanted patients 
during neutropenia are warranted, we have no data 
to change our policy, considering the outcome of 
the reported cases of BSIs. A modern approach to 
the problem of BSIs is probably the investigation 
of the patients' microbioma before allo-SCT. Some 
data from the literature reported that intestinal 
domination, defined as occupation of at least 30 % 
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of the microbiota by a single bacterial taxon, is 
associated with BSI in patients undergoing allo-
SCT, that the gut microbiota can identify high-risk 
patients before allo-SCT and that manipulation of 
the gut microbiota for prevention of BSIs in high-
risk patients may be a useful direction for future 
research.
30,31,32
 Thus, in the near future, we will 
probably need to include this analysis in the 
baseline work up and in the follow up of patients 
addressed to allo-SCT. 
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